Academe Learn
CBME Curriculum Preview

Page 8 of 8

CM19.1-4 | Essential Medicine — PBL Case

CLINICAL SETTING

Dr Kavya Menon joined Korattur Primary Health Centre in coastal Andhra Pradesh six weeks ago as its first permanent Medical Officer after a two-year vacancy. On her first Monday morning, she finds a queue of 40 patients — twice the usual number. The ANM explains that a monsoon cyclone two weeks ago disrupted the district supply chain; the PHC has been out of stock for Oral Rehydration Salts (ORS), Cotrimoxazole tablets, and Metformin 500 mg since then. Three patients in the queue have diarrhoea with signs of moderate dehydration. A fourth patient — a 58-year-old farmer with type-2 diabetes — ran out of his Metformin ten days ago and has come with a blood sugar of 18 mmol/L. As Dr Kavya reviews the drug store, she notices something else: two trays of Amoxicillin 500 mg capsules have packaging with slightly misaligned font and a hologram that differs from the authentic manufacturer specimen in the Drug Quality Reference Binder. The batch number does not appear on CDSCO's track-and-trace portal.

Trigger 1: The Morning Crisis — Stock-outs and a Sick Patient

Dr Kavya must immediately manage the three dehydration cases and the hyperglycaemic farmer without the medicines normally available at the PHC. ORS is on both the WHO EML (28th ed, 2023) and NLEM 2022. Metformin 500 mg also appears on both lists. She calls the Block Medical Officer (BMO) who says the next scheduled supply run is in 10 days. The district drug store may have ORS — but it is 45 km away. She considers: (a) sending an emergency requisition to the district, (b) using 'sugar-salt solution' (SSS) as a temporary ORS alternative, (c) issuing an emergency indent outside the normal quarterly cycle. Meanwhile, the farmer's family offers to buy Metformin from a private pharmacy in town at ₹8/tablet — six times the DPCO ceiling price for the generic.

DISCUSSION POINTS

  • Which medicines involved in this crisis appear on the WHO EML and NLEM 2022, and what does this status mean for their mandatory availability at a PHC?
  • What immediate steps should Dr Kavya take to manage the dehydration patients and the diabetic farmer without the NLEM medicines in stock?
  • Under what mechanisms can a Medical Officer issue an emergency indent outside the quarterly cycle, and what documentation is required?
  • The farmer's family would pay ₹8/tablet vs the DPCO ceiling. What is DPCO, and how does it protect patients from such price exploitation for NLEM medicines?
Click to reveal Trigger 2: The Suspect Amoxicillin — A Quality Alert (discuss previous trigger first!)

Trigger 2: The Suspect Amoxicillin — A Quality Alert

After stabilising the morning patients, Dr Kavya turns to the suspect Amoxicillin capsules. She sends a sample to the district drug testing laboratory. Meanwhile, she receives results from a neighbouring PHC that used capsules from the same batch: two patients reported persistent vomiting and treatment failure for respiratory tract infections — the infections worsened despite three days of Amoxicillin. The district drug inspector arrives and asks Dr Kavya to classify the suspect product using WHO's three-category framework. She also discovers the supplier is unlisted on the CDSCO-approved vendor register. Laboratory results come back the following week: the capsules contain only 48% of the labelled Amoxicillin content, but the packaging outer shows signs of being reprinted over a legitimate manufacturer's original label.

DISCUSSION POINTS

  • Using WHO's three-category framework (substandard, falsified, unregistered), how should Dr Kavya classify this Amoxicillin product? Justify using the laboratory findings AND the packaging evidence.
  • What are the immediate pharmacovigilance steps: which reporting form, which authority (CDSCO, state drug controller, National Pharmacovigilance Programme), and what quarantine procedure?
  • The treatment failures in the neighbouring PHC may represent preventable harm. How do falsified/substandard medicines contribute to antimicrobial resistance — connect the 48% Amoxicillin content to the resistance mechanism.
  • What preventive measures at PHC level (procurement verification, batch testing, SUGAM portal checks) would help detect such products before they reach patients?
Click to reveal Trigger 3: Rebuilding the Drug Store — Rational Indent and Programme Review (discuss previous trigger first!)

Trigger 3: Rebuilding the Drug Store — Rational Indent and Programme Review

Six months later, Dr Kavya has stabilised the PHC. The cyclone disruption is over and normal supply is restored. She is now preparing the annual drug indent for the next financial year. She has consumption data for ORS sachets: 4,800 sachets used last year, with a documented 20% stock-out period. She expects a 15% increase in demand due to a new government nutrition outreach programme targeting under-5 children in the area. The BMO also asks Dr Kavya to present at the monthly District Health Society (DHS) meeting on three monitoring indicators to assess whether the NLEM programme is working at her PHC. Additionally, the Block Pharmacist raises a concern: two colleagues at nearby PHCs are routinely prescribing non-NLEM branded medicines for common respiratory infections — apparently driven by pharmaceutical company incentives.

DISCUSSION POINTS

  • Calculate Dr Kavya's annual indent for ORS sachets using the consumption method: (a) apply the stock-out correction to last year's consumption, (b) apply the 15% demand increase, (c) add a 20% buffer stock. Show each step.
  • Select three WHO/HAI essential medicines programme monitoring indicators most relevant to a PHC. For each, state what it measures and what an ideal benchmark would be (e.g., percentage of prescribed medicines from NLEM; average number of medicines per prescription; percentage of patients who understand their dosing instructions).
  • Dr Kavya wants to adopt the P-drug (personal drug) approach for her own prescribing and introduce it to her PHC staff. Explain the P-drug concept and how it operationalises rational use at the prescriber level.
  • How should Dr Kavya formally report the irrational prescribing pattern at neighbouring PHCs? What institutional mechanisms exist (DTC, District Drug Therapeutic Committee, CMO reporting) to address this without penalising colleagues unfairly?

Group Task Assignments

Group 1: WHO EML and NLEM 2022 Structure

  • Prepare a comparison table of WHO EML (28th ed, 2023: 502 medicines) vs NLEM 2022 (384 medicines, 27 categories) highlighting selection criteria, structure, and three key differences.
  • Identify five medicines common to both lists that are relevant to PHC-level practice in India (e.g., ORS, Cotrimoxazole, Metformin, Amoxicillin, Artemether-Lumefantrine).
  • Present: Why does India's NLEM differ from the WHO EML?

Competencies: CM19.1

Group 2: Rational Use Indicators and P-drug Concept

  • Research the WHO/HAI 12 core prescribing, dispensing, and patient-care indicators for essential medicines programmes.
  • Select the three most relevant indicators for a PHC setting and explain what 'ideal' performance looks like for each.
  • Explain the P-drug approach and prepare a one-page guide for PHC prescribers on selecting a P-drug for acute respiratory tract infections from the NLEM 2022 formulary.

Competencies: CM19.2

Group 3: Substandard and Falsified Medicines — Classification and Prevention

  • Map the WHO three-category framework (substandard, falsified, unregistered) with one real-world documented example for each category from published WHO or Indian regulatory reports.
  • Trace the pharmacovigilance reporting pathway in India for a suspected falsified medicine: from PHC detection to CDSCO alert.
  • Prepare a 'warning card' for PHC pharmacists listing five red flags for identifying suspect medicines at the point of dispensing.

Competencies: CM19.3

Group 4: Drug Requirement Calculation — Consumption Method

  • Explain the three main methods for calculating drug requirements (consumption, morbidity, service level): advantages, limitations, and when each is preferred.
  • Work through the ORS calculation from Trigger 3: stock-out correction → growth adjustment → buffer stock → final indent. Prepare a worked example with formula, steps, and final answer.
  • Draft a one-page quick-reference calculation guide for PHC Medical Officers preparing an annual drug indent.

Competencies: CM19.4

Group 5: DPCO, NPPA, and Medicine Price Regulation

  • Explain how the Drug Price Control Order (DPCO) and NPPA set ceiling prices for NLEM medicines — the mechanism, scope, and limitations.
  • Identify which of the medicines in this case (ORS, Cotrimoxazole, Metformin, Amoxicillin) are under DPCO price control, and what the implications are for private pharmacy pricing.
  • Discuss: Does price control alone ensure medicine access? What other barriers remain?

Competencies: CM19.1, CM19.2

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [CM19.1] What are the selection criteria for inclusion in the WHO Model List of Essential Medicines? How does India's NLEM 2022 differ from the WHO EML in scope, structure, and the medicines it contains?
  2. [CM19.2] What is WHO's rational use of medicines definition, and what are the WHO/HAI core indicators used to monitor essential medicines programme performance at facility level?
  3. [CM19.3] How does WHO classify substandard, falsified, and unregistered medicines? What is the pharmacovigilance reporting pathway in India for a suspected falsified medicine at PHC level?
  4. [CM19.4] What is the consumption method for calculating drug requirements? How are stock-out correction, demand growth adjustment, and buffer stock incorporated into the annual indent calculation?